Richard E. Pratley, MD

Richard E. Pratley , MD

Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute

Translational Research, Infectious Disease

Pratley

Overview

Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.

Articles

Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin

Diabetes technology & therapeutics

2024

Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review

Communications medicine

2024

Risk factors associated with cognitive performance and cognitive impairment in older adults with type 1 diabetes: Data from the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) study

JOURNAL OF DIABETES AND ITS COMPLICATIONS

2024

Dynamic associations between glucose and ecological momentary cognition in Type 1 Diabetes

NPJ DIGITAL MEDICINE

2024

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial

DIABETES OBESITY & METABOLISM

2024

Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial

BMJ OPEN DIABETES RESEARCH & CARE

2024

13. Older Adults: <i>Standards of Care in Diabetes-2024</i>

DIABETES CARE

2024

Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials

Diabetes technology & therapeutics

2023

Associations of Dietary Intake with the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults with Type 1 Diabetes and Overweight or Obesity

JOURNAL OF NUTRITION

2023

Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial

KIDNEY INTERNATIONAL REPORTS

2023

More Publication Information

Education & Training

Education

Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn

Residency

University of Michigan, Ann Arbor, MI

Fellowship

University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT06062069

CT-868-004
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus

Icon for trial | CT-868-004 CT-868-004 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Me

This study is currently enrolling.

Study Purpose: To evaluate the safety and tolerability of the study drug, CT-868, and to study the effect that CT-868 has on Type 1 Diabetes and weight. To be enrolled in this study, you must meet certain requirements. You may ...

FABULINUS: A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for preservation of pancreatic beta-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy.

Icon for trial | DRI17476 FABULINUS: A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for preservation of pancreatic be

This study is currently enrolling.

Study Purpose: The study is aimed to evaluate an investigational drug, frexalimab, for preservation of pancreatic beta cell function in adults and adolescents that have been newly diagnosed with Type 1 Diabetes and started on i ...

NCT04628481

GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 GLADIATOR: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual &beta;-cell function at base

This study is currently enrolling.

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...

REIMAGINE 4 - Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or withouT an SGLT2 inhibitor

Icon for trial | REIMAGINE 4 - Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or withou

This study is currently enrolling.

Study Purpose: The purpose of this study is to look at how much a new investigational medicine called CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to another type 2 diabetes medicine call ...

NCT01843127

GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Ex

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...

NCT04805970

RECODE: Researching Covid Outcomes in Diabetes

Icon for trial | RECODE: Researching Covid Outcomes in Diabetes

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...